A-Raf kinase is a new interacting partner of protein kinase CK2 β subunit  by Boldyreff, Brigitte & Issinger, Olaf-Georg
FEBS 18155 FEBS Letters 403 (1997) 197-199 
A-Raf kinase is a new interacting partner of protein kinase 
CK2 ß subunit 
Brigitte BoldyrerP, Olaf-Georg Issinger 
Biokemisk Institut, Odense Universitet, Campusvej 55, DK-5230 Odense M, Denmark 
Received 12 December 1996 
Abstract In a search for protein kinase CK2 ß subunit binding 
proteins using the two-hybrid system, more than 1000 positive 
clones were isolated. Beside clones for the a' and ß subunit of 
CK2, there were clones coding for a so far unknown protein, 
whose partial cDNA sequence was already deposited in the 
EMBL database under the accession numbers R08806 and 
Z17360, for the ribosomal protein L5 and for A-Raf kinase. All 
isolated clones except the one for CK2 ß showed no interaction 
with the catalytic a subunit of CK2. A-Raf kinase is a new 
interesting partner of CK2 ß. The isolated A-Raf clone 
represented amino acids 268-606, but also a full length A-Raf 
clone interacted with CK2 ß. At the site of CK2 ß, residue 175 
and amino acids between residues 194 and 200 are likely to be 
involved in direct interaction. 
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in the phenotype [12]. In exponentially growing tissue culture 
cells the ß subunit is synthesized in excess of the a subunit, 
although a substantial fraction of the newly synthesized pro-
tein is rapidly degraded [13]. Moreover, an asymmetric expres-
sion of CK2 subunits was observed in human kidney tumors, 
i.e. there is an excess of the ß subunit in tumors versus normal 
tissues when compared to CK2 a [14]. In order to answer the 
question whether CK2 ß interacts with other proteins, a two-
hybrid library was screened with CK2 ß as bait. Among the 
positive clones A-Raf kinase and ribosomal protein L5 were 
found. A-Raf kinase is a new interacting partner, not de-
scribed before. It is one of the three isoforms of Raf kinases 
in mammalian organisms. All are involved in the MAP kinase 
cascade [15]. Most is known about the c-Raf-1 isoform, which 
plays an essential role in the control of cellular proliferation 
and transformation. But little is known about potential spe-
cific functions and regulation of the two other isoforms A-Raf 
and B-Raf [16]. 
1. Introduction 
Protein kinase CK2 is a ubiquitously expressed and highly 
conserved pleiotropic serine/threonine protein kinase (for re-
views see [1-3]). Its activity and quantity have been shown to 
be elevated in proliferating cells. Despite numerous reports on 
its potential role in proliferation and tumorigenesis, the regu-
lation and physiological role of CK2 are not understood. CK2 
consists of two catalytic (a) and two regulatory (ß) subunits, 
which form the tetrameric 0:2 ß2 holoenzyme. Once formed, 
the holoenzyme cannot be dissociated into its subunits except 
under denaturing conditions. The role of the ß subunit in the 
holoenzyme complex is to modulate the activity of the a sub-
unit, to contribute to the substrate specificity and to confer 
stability to the a subunit [4,5]. Furthermore the stimulation of 
CK2 activity by polybasic compounds is mediated through the 
ß subunit [6]. In two-hybrid experiments it has been shown 
that one ß subunit can interact with another ß subunit, but 
also with the a or a ' subunit [7,8]. This supports the notion 
that ß dimerization precedes binding of two a subunits and 
formation of the holoenzyme. Moreover CK2 ß also binds to 
other proteins, e.g. p53 and ribosomal protein L5 [9-11]. p53 
copurifies with CK2 and its binding is mediated by the ß 
subunit. However, there is some evidence that the ß subunit 
might have some other roles in the cell beside as a subunit of 
CK2. Studies in Schizosaccharomyces pombe have shown that 
the overexpression of CK2 ß leads to inhibition of cell growth 
and cytokinesis with formation of multiseptate cells, whereas 
overexpression of CK2 a did not lead to any visible alteration 
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2. Materials and methods 
2.1. Screening a two-hybrid library with CK2 ß as bait 
Human CK2 ß was cloned into the vector pGBT9 [17] as a fusion 
with the Gal4 DNA binding domain [7] and transformed into yeast 
Saccharomyces cerevisiae strain HF7c [18]. Sequential co-transforma-
tion with a HeLa cDNA library with 7X106 independent clones 
cloned in pGADGH as a fusion with the Gal4 activation domain 
(Clontech) was carried out. Co-transformants were plated on syn-
thetic medium lacking tryptophan, leucine and histidine and contain-
ing 20 mM aminotriazole. Growing clones were further monitored for 
activation of the LacZ reporter gene in filter and/or liquid assays (see 
below). From seven of the positive clones the library Gal4 DNA 
activation domain plasmid was isolated by growing them in synthetic 
medium lacking only leucine and sequenced. 
2.2. Direct CK2 $1 A-Raf interaction tests 
The yeast strain HF7c was cotransformed with a full length Raf 
construct cloned in p533 and a CK2 ß wild-type clone or CK2 ß 
mutant constructs cloned in pGAD424 [7]. p533 is a derivative of 
pPC97 in which the Leu marker was replaced by the Trp marker of 
pPC86, in order to make selection possible for transformation togeth-
er with pGAD424, containing the Leu marker. This full length A-Raf 
construct was kindly provided by U. Rapp (University of Würzburg, 
Germany). After selection of transformants a filter assay to monitor 
the expression of the LacZ reporter gene was carried out. 
2.3. ft-Galactosidase filter and liquid assay 
For the filter assay single colonies were picked and transferred to a 
Whatman No. 5 filter paper which was further incubated on a fresh 
plate for 2-3 days. The filters were frozen in liquid nitrogen, then 
layered over a second filter prewetted with Z-bufTer (16.1 g/1 
Na2HP04-7H20, 5.5 g/1 NaH2P04-H20, 0.75 g/1 KC1, 0.246 g/l 
MgS04-7H20) which contained 0.27 ml 2-mercaptoethanol and 1.67 
ml X-gal (20 mg/ml in dimethylformamide) per 100 ml. Incubation 
was done at 30°C for up to 12 h. 
For the liquid assay 5 ml cultures with synthetic medium were 
inoculated with single colonies and grown until A$a$ = 1. 500 u.1 and 
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Fig. 1. Interaction of A-Raf with CK2 ß™* and mutants. In direct two-hybrid tests the interaction between the full length A-Raf and different 
CK2 ß constructs was examined by activation of the HIS and LacZ reporter genes. +, both reporter genes were activated; —, neither of the re-
porter genes was activated. Numbers above refer to amino acids. Regions of CK2 ß r t with known functions are marked by boxes: 2, auto-
phosphorylation site; 55-65, involved in a/ß interaction and in polylysine effect; 155-165, critical for ß/ß dimerization; 170-193, involved in at-
tenuation of dimerization and tetramer formation. 
1 ml of each culture was transferred to a microcentrifuge tube and 
centrifuged for 5 s. The yeast pellet was dissolved in 100 ul Z buffer 
(see above) and frozen in liquid nitrogen. After thawing, 700 ul Z 
buffer with mercaptoethanol (see above) and 160 ill ONPG (4 mg/ 
ml in Z buffer, freshly prepared) were added and the reaction was 
incubated for 1 h at 30°C. The reaction was stopped by addition of 
400 ul 1 M Na2CC>3, after centrifugation for 10 min in a microfuge at 
maximum speed, the 4^20 was measured. ß-Galactosidase activity was 
calculated in Miller units according to the following formula: 
units=1000X^42o/(culture volume in ml X incubation time in 
minX^eoo). 
2.4. DNA sequencing analysis 
The sequencing was carried out by the dideoxy chain termination 
method. Sequence homology searches were done using the GenEMBL 
database. 
strong interacting partners of CK2 ß. From these first 164 
clones seven were randomly chosen for further analysis. The 
containing library activation domain fusion construct was iso-
lated and sequenced. In six cases sequence homology search 
identified the encoded proteins. We found the CK2 ß subunit 
three times and the CK2 oc' subunit, the ribosomal protein L5 
and the A-Raf kinase once. The sequence of the remaining 
clone #35 matched with more than 90% sequence identity two 
sequences in the database (accession numbers R08806 and 
Z17360), but the encoded protein is so far not known. 
The CK2 ß and a ' clones contained full length cDNAs, 
whereas both the L5 and the A-Raf clone contained only a 
3'-part of the cDNA; in the case of L5 it started with the 
3. Results and discussion 
3.1. Library screening 
After transformation of the CK2 ß construct containing 
cells with the library and plating, first approximately 3000 
clones where obtained where the HIS reporter gene was acti-
vated. 164 of these clones appeared 3 days after plating, 1369 
after 4 days, 813 after 5 days and 645 after 7 days. Of the first 
164 clones all were able to activate the second reporter gene 
LacZ, whereas in only approximately half of the later appear-
ing clones the second reporter gene was activated. Altogether 
we had isolated ~ 1500 clones positive for both reporter 
genes. However, only the first 164 clones represent probably 
Table 1 
Detection of interaction between CK2 ß and library proteins from 
the two-hybrid screen 
Library protein Growth on ß-Galactosidase 
CK2 ß 






















The interaction was determined by growth on —His medium (activa-
tion of HIS reporter gene) and quantitative and qualitative assays for 
ß-galactosidase (activation of LacZ reporter gene). 
"Activity values are given in Miller units as mean values ± standard 
deviation from three different experiments. 
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codon for amino acid 108, in the case of A-Raf with the 
codon for amino acid 268, both cDNA sequences ended 
with the poly-A tail. 
The interaction between CK2 ß and the 5 identified library 
constructs is shown in Table 1. The CK2 ß/ CK2 a ' interac-
tion seems to be the strongest (19.3 Miller units), whereas all 
others are in a lower range between 1.1 and 5.8 Miller units. 
In this latter range also interaction between CK2 ß and oc was 
determined (not shown). A similar difference in strength of 
interaction between CK2 ß and the two CK2 a isoforms 
has been previously published by Gietz et al. [8]. 
All obtained clones were tested to see whether they would 
also interact with the catalytic CK2 a subunit. This was the 
case for none of the clones except CK2 ß. 
The identified interacting partners CK2 ß and a ' did not 
come as a surprise, also interaction with ribosomal protein L5 
was reported recently by Kim et al. [11]. In a two-hybrid 
screen with CK2 ß they found the C-terminal portion of L5 
starting with amino acid 153, whereas the clone isolated here 
started at amino acid 108. A new interacting partner for CK2 
ß is the A-Raf kinase. 
3.2. Interaction of CK2 ß with A-Raf 
The isolated A-Raf clone interacting with CK2 ß contained 
the region of the cDNA coding for amino acids 268-606. This 
region includes the kinase domain of A-Raf [19]. The inter-
action between CK2 ß and A-Raf was further investigated 
using a full length A-Raf construct. This construct also re-
vealed interaction with CK2 ß. In contrast to a truncated 
molecule consisting of only the kinase domain the full length 
A-Raf is not catalytically active by itself and seems to have a 
different conformation [16]. However, it still allows interac-
tion with CK2 ß. 
Several CK2 ß C-terminal deletion mutants (1-200, 1-193, 
1-180, 1-170, 1-165, 1-155 and 1-149) and three point muta-
tions (A171, A175 and A177,178) were tested in order to map 
the specific sites required for that interaction. Direct two-hy-
brid tests were performed using the full length A-Raf and the 
different CK2 ß deletion and mutation constructs (Fig. 1). The 
deletion mutant CK2 ß (1-200) did reveal interaction with A-
Raf, but the next deletion mutant (1-193) had lost this ability. 
Also all larger deletions were negative. Since CK2 ß (1-193) is 
still capable of interacting with CK2 a (Boldyreff and Issing-
er, unpublished results) one should assume that this deletion 
causes no big structural changes. This suggests that residues 
194-200 could be at least part of the binding site for A-Raf. 
The three point mutations of CK2 ß tested for interaction 
with A-Raf led to a rather surprising result. One mutant, 
CK2 ß A175, completely abrogated the interaction, whereas 
the others were able to interact. CK2 ß residues 175, 177 and 
178 seemed to be involved in attenuation of the ß-ß dimeriza-
tion [7]. But in all biochemical tests the corresponding mu-
tants behaved like wild-type ß, especially when they were 
tested to replace the wild-type ß in a tetrameric complex 
with CK2 a [20]. Therefore it seems unlikely that the single 
exchange mutant Al75 leads to big conformational changes 
which might be the reason for prevention of A-Raf interac-
tion. It seems more likely that residue 175 of CK2 ß is directly 
involved in interaction. 
Amino acids critical for interaction with the a subunit were 
mapped to amino acids 152-200 [21] and to 170-193 (Boldyr-
eff and Issinger, unpublished results). Therefore it could well 
be that binding of A-Raf to CK2 ß interferes with binding of 
CK2 oc. Since CK2 ß exists as a dimer that interacts with two 
CK2 oc monomers to form the active, heterotetrameric CK2 
enzyme, heterotetramerization with e.g. two A-Raf molecules 
might be also possible. 
Our data suggest that CK2 ß could be involved not only in 
forming a tetrameric protein kinase CK2 holoenzyme but also 
in binding to and possibly regulating other proteins. Both 
interacting proteins, ribosomal protein L5 and A-Raf kinase 
are interesting partners of CK2 ß opening a new area for the 
understanding of the physiological role of protein kinase CK2 
and its subunits. 
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